Identification of Potential Biomarkers of Response to Peptide

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

See also
Status	Clinical Trial	Phase
Completed	`NCT01198613` - ToleroMune Ragweed Exposure Chamber Study	Phase 2
Recruiting	`NCT05346718` - Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis	N/A
Completed	`NCT01448603` - ToleroMune Ragweed Follow up Study	N/A
Completed	`NCT01398137` - Ragweed Observational Study	N/A
Completed	`NCT02396680` - Ragweed-SPIRE Follow-On Study	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT01198613 - ToleroMune Ragweed Exposure Chamber Study

Phase 2

Recruiting

NCT05346718 - Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis

N/A

Completed

NCT01448603 - ToleroMune Ragweed Follow up Study

N/A

Completed

NCT01398137 - Ragweed Observational Study

N/A

Completed

NCT02396680 - Ragweed-SPIRE Follow-On Study

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01361412
Study type	Interventional
Source	Circassia Limited
Contact
Status	Completed
Phase	Phase 2
Start date	March 2011
Completion date	September 2011

Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms